Bibliography
- Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
- Gründer G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov 2009;8:197-202
- Sikich L, Frazier JA, McClellan J, Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008;165:1420-31
- Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. NEJM 2005;353:1209-23
- Jones PB, Barnes TRE, Davies L, Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87
- Leucht S, Komossa K, Rummel-Kluge C, A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
- Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-9
- Green MF. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry 2007;164:992-4
- Keefe RS, Sweeney JA, Gu H, Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007;164:1061-71
- Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand 2007;115:4-11
- Ishibashi T, Horizawa T, Yabuuchi K, Receptor binding characteristics of SM-13496, a novel atypical antipsychotic agent. Poster presentation at the society for neuroscience annual meeting, November, 2008
- Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci 2004;25:481-6
- Meneses A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping pavlovian/instrumental learning task. Behav Brain Res 2004;155:275-82
- Guscott M, Bristow LJ, Hadingham K, Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression. Neuropharmacol 2005;48:492-502
- Mnie-Filali O, Lambas-Senas L, Zimmer L, Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007;20:613-18
- Abbas AI, Hedlund PB, Huang X-P, Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology 2009:1-10; advanced online publication 01 April 2009
- Galici R, Boggs JD, Miller KL, Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav Pharmacol 2008;19:153-9
- Semenova S, Geyer MA, Sutcliffe JG, Inactivation of the 5-HT7 receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry 2008;63:98-105
- Suckling CJ, Murphy JA, Khalaf AI, M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds. Bioorg Med Chem Lett 2007;17:2649-55
- Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195:30-8
- Ishibashi T, Ohno Y, Horisawa T, In vitro and in vivo pharmacological profiles of lurasidone, a novel antipsychotic agent with a potent 5-HT1A/7 receptor action. Psychopharmacol (Berlin): under review
- Ishibashi T, Tokuda K, Kishino A, Preclinical pharmacological property of lurasidone, a novel atypical antipsychotic agent: I. Antipsychotic actions and minimum side effects. Poster presentation at the annual IPA meeting, 2007
- Ishiyama T, Matsumoto Y, Tokuda K, Effects of SM-13496, a novel serotonin-dopamine antagonist, and other antipsychotics on cognitive performance in the rat passive avoidance test. Poster presentation at the 33rd annual society for neuroscience meeting, New Orleans, November, 2003
- Ishiyama T, Tokuda K, Ishibashi T, Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572:160-70
- Enomoto T, Ishibashi T, Tokuda K, Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186:197-207
- Mohamed S, Rosenheck R, Swartz M, Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008;165:978-87
- Nakamura M, Ogasa M, Guarino J, Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009:e1-e8; advanced online 2 June 2009
- Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacology 2009;19:34-40
- Kemp AS, Schooler NR, Kalali AH, What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 2008:1-6; advanced online published 22 August 2008
- Stroup TS, Lieberman JA, McEvoy JP, Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22
- McEvoy JP, Lieberman JA, Stroup TS, Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10
- Conn PJ, Tamminga C, Schoepp DD, Schizophrenia: moving beyond monoamine antagonists. Mol Interv 2008;8:99-107
- Kraepelin E. Dementia praecox and paraphrenia. New York, Krieger; 1971
- Nuechterlein KH, Barch DM, Gold JM, Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39
- Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41-51
- Buchanan RW, Freedman R, Javitt DC, Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schiz Bull 2007;33:1120-30
- Carter CS, Barch DM, Buchanan RW, Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the cognitive neuroscience treatment research to improve cognition in schizophrenia initiative. Biol Psychiatry 2008;64:4-10
- Harvey PD, Ogasa M, Cucchiaro J, Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Bull 2009;35(Suppl 1):s357
- Janssen Pharmaceutica. Invega package insert. Titusville, NJ; 2008
- Vanda Pharmaceuticals, Inc. Fanapt package insert. Rockville, MD; 2009
- Schering-Plough Corporation. Saphris package insert. Kenilworth, NJ; 2009
- Glick ID, Peselow ED. New antipsychotic agents. Prim Psychiatry 2008;15:57-64
- Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12:904-22
- Patil ST, Zhang L, Martenyi F, Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
- Available form: http://www.schizophreniaforum.org/new/detail.asp?id=1510 [Accessed 6 June 2009]
- Shekhar A, Potter WZ, Lightfoot J, Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 2008;165:1033-9
- Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatrica Scandinavica 2009;119:4-14
- Pfizer, Inc. Geodon package insert. New York, NY; 2006
- Bristol-Myers Squibb. Abilify package insert. Princeton, NJ; 2008
- Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008;33:2061-79